As I look back at my nearly 15 years as Department Chair, one of the areas that I am most proud of is the growth and excellence in the Division of Hematology and Oncology. Fifteen years ago, the Division was relatively small, with minimal research and searching for an identity. Under the leadership of Mike Williams, Karen Ballen, Tom Loughran, and many others, the Division has grown significantly, the Cancer Center now has Comprehensive status, and the research has exploded. There is much to be excited about, and patients benefit daily from our clinicians’ expertise. More than ever, the diagnosis of cancer is being transformed as new therapies make their way to the bedside. I would encourage you to read this month’s newsletter to get a sense of the depth, breadth, and excellence of the Division and the care, education, and research that it delivers.

Also in this month’s newsletter are the year’s residency match results. I thank Dr. Brian Uthlaut and his team for their dedication and efforts in attracting the best students to join our program. As you will see, this year’s class represents a diverse group of young residents who will continue the tradition of excellence in this critical program. Thanks to all who have served as interviewers as well.

Lastly, I wanted to update you on the work of the DOM Compensation Committee. The committee has now been formed and has met twice to review the basic schematic of the compensation plan. They will soon start working on developing incentive criteria. There is a tremendous amount of work to be done. Still, I am sure that under the leadership of Dr. Taison Bell, our committee will develop thoughtful recommendations that recognize the contributions of all faculty.

With best wishes,

Mitchell H. Rosner, MD, MACP
Henry B. Mulholland Professor of Medicine
Chair, Department of Medicine
DOM Financial Update

Department of Medicine
Summary of Consolidated Financials
FY21 as of February 2024

<table>
<thead>
<tr>
<th>Budget YTD</th>
<th>Actual YTD</th>
<th>$ Variance YTD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Work RVUs</td>
<td>791,367</td>
<td>834,733</td>
</tr>
<tr>
<td>Clinical Receipts (NPSR)</td>
<td>50,773,576</td>
<td>54,228,904</td>
</tr>
<tr>
<td>Total Revenues</td>
<td>144,025,711</td>
<td>154,129,876</td>
</tr>
<tr>
<td>Total Expenditures</td>
<td>142,497,829</td>
<td>153,201,007</td>
</tr>
<tr>
<td>Net Income</td>
<td>1,527,883</td>
<td>928,870</td>
</tr>
</tbody>
</table>

Summary Explanation of Variance:
For the fiscal year through February 2024, DOM reported a consolidated net gain of $928K and an unfavorable variance to YTD net income budget of $599K. Clinical receipts surpassed budget by $3.5M primarily due to strong productivity, unbudgeted Community Oncology and APP charge volumes. Total revenues include $1.7M Endowment revenue recorded for March through June and $1.8M clinical deficit coverage revenue accrual. Total revenue is missing $1.3M in missing clinical agreements and revenue contingencies. Total expenditures variance is unfavorably impacted by $5.1M increased spending related to grants and commitments, $2.5M unbudgeted CommOnc Expenses, $1.1M unbudgeted ICU Culpeper APPs and unbudgeted APPs night and weekend shifts and $1.3M budgeted expenditure reduction contingencies.

Do You Have News You’d Like To Share on Medicine Matters?
Contact Kim Kelley-Wagner kak2cj@virginia.edu
434.328.0680

Welcome To The World

Congratulations to Caleb (Resident) and wife Lauren who welcomed baby Charlotte McKinney on February 26, 2024.

Congratulations to Jessica Dreicer (General Medicine) and husband Ryan McCrystal who welcomed baby Livvy Rey on March 4, 2024.
DOM UPDATES & NOTES

Awards and Achievements

Congratulations to Dr. Rasheed Balogun (Division of Nephrology) on receiving the American Society for Apheresis (AFSA) Presidential Award. The Awards Committee selected Dr. Balogun for his commitment to apheresis and consistency in contributing to and performing outstanding service for the Society over many years. This is a distinguished award; we are very proud of his accomplishments. Read more...

Congratulations to Dr. Monica Lawrence (Division of Asthma, Allergy, and Immunology), named Designated Institutional Official (DIO) and Associate Dean for Graduate Medical Education. Dr. Lawrence will supervise all GME programs, overseeing 850 residents, fellows, and trainees across our organization. Read more...

Congratulations to Dr. Michelle Tran (Division of Nephrology fellow), who was selected as an American Society for Nephrology Excellence in Patient Care Intern to promote the prevention and treatment of Acute Kidney Injury. Read more...

Congratulations to Dr. Patricia Rodriguez Lozano (Division of Cardiovascular Medicine), who has been chosen as one of the 50 learners for American College of Cardiology’s (ACC) 2024-2025 Clinical Trials Research program. She will be among the 28 structural heart cardiologists and surgeons in Project REACH. Learn more...

Congratulations to Dr. Pamela Mason and team, with the support of cardiac surgery and cardiac anesthesia, (Division of Cardiovascular Medicine), on performing the first extravascular implantable cardioverter defibrillator (ICD) in Virginia. Read more...

FOLLOW UVA SCHOOL OF MEDICINE DIVERSITY & INCLUSION

FOLLOW UVA WOMEN IN INTERNAL MEDICINE NETWORK

In Good Health: The Nation’s Hydration Fixation (A1/NPR)

Does it seem like everyone is carrying around a 30-ounce tumbler? The reusable water bottle industry is a multi-billion dollar business. But don’t forget about plastics. The sales of single-use bottled water also continue to rise.

We’re a nation intent on hydration. But how much of the hype around water is marketing versus science? Dr. Mitch Rosner helps answer that question and more.

LISTEN NOW

Why Are We Still Flu-ifying COVID? (The Atlantic)

COVID vaccines are now reformulated annually, and recommended in the autumn just like flu shots; tests and treatments for the disease are steadily being commercialized, like our armamentarium against flu.

Some of those decisions are “not completely unreasonable,” says Costi Sifri, the director of hospital epidemiology at UVA Health, especially on a case-by-case basis. But taken together, they show how bent America has been on treating COVID as a run-of-the-mill disease—making it impossible to manage the illness whose devastation has defined the 2020s.

READ MORE
In Media

7 Quick Questions With Heart Rhythm Specialist Rohit Malhotra, MD
Dr. Malhotra, is a heart rhythm disorders specialist and cardiac electrophysiologist. He was one of the first doctors at UVA Health to implant a special type of pacemaker that doesn’t use wires and instead goes directly into the heart.

READ MORE

COVID-19 vaccines: CDC says people ages 65 and up should get a shot this spring – a geriatrician explains why it’s vitally important (The Conversation)
As spring 2024 fast approaches, the CDC reminds Americans that even though the public health emergency is over, the risks associated with COVID-19 are not.

Dr. Laurie Archbald-Pannone discusses the risks and recommendations.

READ MORE

Colon Cancer Killing Young Men, Women at Troubling Rate: Study (News Nation)
Colon cancer has become the leading cause of death among men younger than 50, and the number two cause of death in women of the same age group, according to the report.
Researchers pointed to the possibility that the COVID-19 pandemic caused delays in the diagnosis and treatment of cancer in 2020 because of health care setting closures and fear of virus exposure.

Dr. Ross Buerlein, joined “NewsNation Prime” to discuss the troubling rates of colon cancer, saying regular screenings are the best form of prevention.

WATCH NOW

CDC Guidelines for COVID Isolation Change (NBC29)
The CDC says people who test positive for COVID-19 no longer need to isolate for five days.

“We still have people dying of COVID every week at UVa,” UVA Health Associate Professor of Medicine Doctor Kyle Enfield said, “So, it’s not a disease that has left our environment. It just seems to be less severe now.”

According to new CDC guidelines, people who test positive for COVID-19 do not need to isolate unless they have a fever.

WATCH NOW

Follow DOM on INSTAGRAM!
A nagging cough can hang on for weeks or months following a respiratory illness – and there is precious little you can do about it (The Conversation)

A cough is a common symptom of these sorts of respiratory infections, and coughing is a complaint that leads to an estimated 30 million office visits every year. But a cough following an upper respiratory infection does usually go away, in time.

Blood Test Could Predict Risk of Long-Term COVID-19 Lung Problems (UVA Today)

Up to 30% of patients hospitalized with severe COVID-19 continue to suffer persistent symptoms months after recovering from the virus. Many of these patients develop lung scarring – some early on in their hospitalization, and others within six months of their initial illness, prior research has found.

Dr. Catherine Bonham and her collaborators wanted to better understand why this scarring occurs, determine if it is similar to progressive pulmonary fibrosis and see if there is a way to identify patients at risk.

UVA Researchers Develop Online Dashboard to Help Save Children From Deadly Diarrhea

Josh Colston, PhD and team are developing a powerful online tool to save children from deadly diarrhea by detecting outbreaks sooner and accelerating the deployment of treatments and new vaccines. Diarrhea not only kills hundreds of thousands of children every year, it contributes to malnutrition and muscle wasting that stunt kids’ growth, harms their mental development and helps trap them in poverty. While significant progress has been made against the disease in recent years, the UVA researchers say that the modern era of “big data” offers a vast untapped opportunity to respond more nimbly and help more children.

With spring in full swing, UVA Health’s Dr. Jeffrey Wilson discusses the factors that trigger seasonal allergies (29News)

The Asthma and Allergy Foundation of America says Virginia has two cities listed in the top 10 for the worst cities for people with allergies. They are Virginia Beach and Richmond.
In Media

**Community Conversation: Dr. David Callender with UVA Health (NBC29)**

Dr. David Callender discusses colorectal cancer screening with NBC29

WATCH NOW

**Kate McManus, MD, Helps Us Connect With COWIMS as it turns 20**

UVA School of Medicine launched COWIMS 20 years ago in 2004. Dr. McManus has been COWIMS chair since 2022.

READ MORE

**New Advance Against a Form of Heart Failure Prevalent in Men (TIME)**

Kenneth Walsh, PhD, and his research team discovered how Y chromosome loss triggers changes in heart immune cells that make the cells more likely to cause scarring and heart failure.

READ MORE

**How Hypertrophic Cardiomyopathy Progresses in Adults (TIME)**

Dr. Christopher Kramer, School of Medicine, comments on the complexities in the diagnosis and timing of hypertrophic cardiomyopathy.

“It’s an incredibly heterogeneous disease, and the more we learn about it, the more complex it gets,” he says.

READ MORE

**GET A NEW PROVIDER DIRECTORY HEADSHOT**

McKim Hall | Ground Floor, Room G045

Physicians and advanced practice providers: get a new or updated headshot taken in 10 minutes or less on dates listed below. No appointment needed. Bring a white coat if you have one; if not, one will be provided.

- Tuesday, April 2 | 9 a.m. - noon
- Thursday, April 11 | 11 a.m. - 2 p.m
- Wednesday, April 17 | 10 a.m. - 1 p.m.
- Friday, April 26 | noon - 3 p.m.
- Monday, April 29 | 9 a.m. - noon
Social Media and Information

UVA Department of Medicine
H. Charles Malpass III Memorial Grand Rounds

Friday, May 24, 2024
ERC Auditorium (or Zoom)
12 p.m.-1 p.m.

Dr. Cynthia Brown joins us from Indiana University to celebrate the legacy of Dr. H. Charles Malpass III (Charlie). Dr. Malpass, an amazing father, husband, brother, son, runner, and clinician, passed away suddenly on September 14, 2023.

Charlie was renowned for his dedication as a pulmonary physician at UVA Health, specializing in interventional pulmonary and bronchoscopy. He worked tirelessly to provide diagnostic lung results and guidance for his patients, even while facing his battle with acute myeloid leukemia (AML).

Like Charlie, Dr. Brown is esteemed for her dedication to fellow education and patient care. We hope you will join us for the May 24th Grand Rounds as we remember Dr. Malpass and celebrate his enduring impact on the medical community.

Cynthia D. Brown, MD
Professor of Clinical Medicine
Adult Cystic Fibrosis Director
Indiana University

MINFULNESS MATTERS
A Newsletter from the UVA Mindfulness Center

UVA Resources for Team Members
support for dealing with crisis and how to stay informed.

FOLLOW UVA ID
FOLLOW UVA ENDO
FOLLOW UVA PULMONARY
FOLLOW UVA NERPHROLOGY
FOLLOW UVA CARDIO
FOLLOW GASTRO

DOM UPDATES & NOTES

Is Your Content Up-to-Date?

Our department websites are one of the most powerful recruitment tools we have, and to use them effectively, we need your help to keep our content up-to-date.

Please check your Division’s DOM site for wherever you appear to be sure all information is current.

Researchers and lab managers, if you don’t already have a research page dedicated to your team, please get in touch with Kim Kelley-Wagner to get started at kak2cj@uvahealth.org or 434.328.0680

Need a team photo or a research lab photo shoot? Contact Kim Kelley-Wagner.

Thanks for making our websites a valuable and dynamic experience!

COME SEE HOOS RUNNING WITH GIM!

‘Run with GIM’ (General Internal Medicine) would love for all interested to join us at 5pm every Wednesday across from the South garage on the corner of Jeanette Lancaster and Crispell Dr.

Run with GIM is a non-competitive, all-inclusive running group focused on building wellness and growing camaraderie.
Events

Come Out and Join and/or Ride In Support of ALS Research

Internal Medicine group will ride out in support of ALS research again this May 5th in Crozet. Anyone is welcome to join them by contacting Patrick Dillon or using the link below. Various distances are available, including a children’s ride. Non-riders are also invited to the event, so please come out in support. Take a look at photos from last year!

2024 Ride to Defeat ALS: Blue Ridge: UVA Internal Medicine - The ALS Association (convio.net)

UVA’s contenders include a discovery by Jeffrey Wilson, MD, PhD, and colleagues that found that sensitivity to common food allergens such as dairy and peanuts could be an important and previously unappreciated cause of deadly heart disease, even in people without obvious food allergies. That risk could equal or exceed the risk posed by smoking.

Voting in the first round of STAT Madness continues for seven days, and the championship round concludes April 4 - so there’s still time! Make sure to vote UVA every day!
In Media

Do Good at Work: How Hank Brings Joy to Students, Team Members, and Patients

Joy Hilton Early wears two hats at UVA Health. One: at UVA School of Medicine, where she’s served for more than 14 years as the Director of Education for the Department of Medicine — managing educational administrators and coordinators for the department’s graduate and undergraduate medical education programs.

The other hat: Joy, along with her three-and-a-half-year-old English Labrador retriever, Hank, are weekly Pet Therapy Program volunteers at UVA Health.

In 2020, when Joy brought Hank home when he was just eight weeks old, she wasn’t intending to raise a therapy dog — Hank was Joy’s pandemic puppy.

Joy knew Hank was going to be a big dog, and she wanted to ensure he was well behaved, especially around Joy and her husband Stephen’s eight grandchildren.

Read entire article in CONNECT

White House Leaders Visit UVA Comprehensive Cancer Center Following President Biden’s State of the Union Address

The White House is partnering with the University of Virginia as part of President Biden’s Cancer Moonshot, a national effort to end cancer. On Thursday evening in advance of Biden’s State of the Union address before Congress, the administration announced that UVA’s is one of 40 comprehensive cancer centers and community oncology practices that have committed to using new patient navigation services paid for by seven of the nation’s leading health insurance companies. The services are designed to help patients and their caregivers more easily understand and access the complicated cancer treatment process.

Read More...
Happy Match 2024! Below is the roster of our newest University of Virginia residency-matched class (aka The Class of 2027)! It is an outstanding group, and we are excited to welcome you to the program this summer!

This is now year 4 of virtual interviews and our second that included optional in-person open houses in February. Many thanks to our residents, faculty reviewers and interviewers, admin team, and especially our chief residents—Kara Harrison, Joe Mort, John Popovich, and Margo Tanner for all their hard work in welcoming, interviewing, and teaching more than 500 interviewees. This year’s group is distinguished academically and in leadership and service. It is one of our most geographically widespread matches, so please welcome these new physicians as they become part of the UVA family and contribute to our missions of patient care, education, research, diversity, equity, and community engagement.

Brian Uthlaut MD
Associate Professor of Medicine
Residency Program Director and Vice Chair of Education
Department of Medicine

Happy Match Day
LEARN MORE & WATCH VIDEO
Education Update

ACGME Conference Presentations
Department of Medicine’s central education team members traveled to Orlando in early March to participate in this year’s annual ACGME (Accreditation Council for Graduate Medical Education) conference – “Meaning in Medicine.” In addition to participating in various plenary and workshop sessions, team members Joy Hilton Early, Terry Bennett, Brittany Davis, and Lizzie Daniels were presenters for two conference workshops.

Utilizing Instagram and Creating Your Brand: The Ultimate Recruitment Tool – Presentation by Brittany and Lizzie

Workshop Description
Graduate medical education (GME) recruitment has transformed from an in-person experience to a virtual platform. Programs and applicants have had to learn to navigate and prosper in a virtual recruitment world. The use of technology has been critical in doing so. Social media has become an effective tool that is being utilized to create a program’s digital presence and reach its target audience. One social media platform that is being used by many GME programs across the country is the notorious Instagram.

Brittany and Lizzie discussed the transformation of GME recruitment to a virtual platform and its dependence on technology. They provided a roadmap for programs that utilize Instagram as the ultimate recruitment tool. They discussed the importance of building a program’s brand and creating a digital presence for their target audience. They also provided tools for developing content and best practices for engaging on the social media platform. It was noted that Instagram can be used to advertise and promote your program’s offerings to applicants and showcase your program, institution, geographic location, and day-to-day life as a trainee.

Roadmap to Recognition – Building Our Professional Reputation One Milestone at a Time – Presentation by Joy, Terry, and Brittany

Workshop Description
In 2013, the University of Virginia’s Medicine Education Team crafted “Milestones for Program Administrators” concurrent with the ACGME’s accreditation model (“the Next Accreditation System) and Milestones Project. The intent was to demonstrate the relevancy of Milestones’ achievement to program support staff members and to elevate their professional acumen and graduate medical education (GME) reputation.

Flash forward to 2024

Workshop Description
In this workshop, presenters described the scenario leading up to, during, and following the COVID-19 pandemic and the need to re-evaluate their core competencies and milestones for program administrators in a similar fashion to the ACGME’s Milestones 2.0 updates. The workshop included a brief background and history of how their team of GME administrators collaborated to review and revise the Milestones, focusing on areas that required updates to their roles (e.g., technical skills around virtual learning/recruitment and challenges to well-being posed by remote and/or hybrid work models). They presented data gathered from their pilot project, whereby program administrators and supervisors from across the country utilized their milestones to conduct self-assessments and draft professional development “smart goals.” Also, they presented sample “smart goals” and solicited participant discussion and feedback on the proposed milestones. They aim to partner with others in the GME community to solidify program administrators’ professional status and credibility by creating standardized milestones that local institutions, subspecialty associations, and national accreditation entities will ultimately endorse.

Lizzie (left) and Brittany (right) in front of their workshop screen and taking a selfie with participants in the background.

Katie Christie (Neurology Education Coordinator), Lizzie, and Brittany pictured with Jason Reminick, CEO and Founder of Thalamus (a residency application and interview management platform).
I am so proud to present the accomplishments of our incredible Hematology/Oncology team. We have had another banner year in clinical care, research, education, and community engagement.

In the past year, we have had the good fortune to recruit four new clinical faculty, with two physicians starting this coming summer. Dr. Danny Reed, who trained with us at UVa, joined us in our growing Leukemia program. Dr. Muneeb Rehman, a Gastrointestinal Oncology specialist, is an integral member of our very busy GI Oncology Team. Dr. Krithika Shanmugasundaram, a Chimeric Antigen Receptor (CAR)-T cell expert, recently joined our busy Stem Cell Transplant program. Dr. Balraj Singh is pioneering our expansion into Northern Virginia, working at Prince William and Culpeper. This summer, we are excited to welcome Dr. Nate Roberts, one of our Heme/Onc fellows, who will join our Lymphoma Team. Dr. Ludi Cavalcante, a sarcoma expert, will lead our Medical Sarcoma program and expand our Phase I effort—many thanks to our Administrative Specialists and Search Committees for the time and hard work of successful recruitment.

Congratulations and thanks to our Advance Practice Provider lead, Jessica Kassay-McAllister and Susie Herndon. Our APP program continues to expand. APPs Scott Cook, Kristen Noonan, Jordyn Sewell, and Jenea Brown are joining our team this year.

Our Cancer Service Line, is led by Dr. Mike Williams, former Division Chief, an international lymphoma expert, and my mentor, friend, and neighbor. Mike has transitioned to this role but remains active in mentorship, education, and scholarship. We welcome and congratulate Dr. Leigh Cantrell on her role as our Cancer Service Line Lead.

We are exceedingly proud that 22 of our providers were recognized for achieving Press-Ganey scores above the 90th percentile. UVA Oncology clinics in Augusta, Culpeper, and Pantops all achieved the coveted Number 1 honor for UVA Ambulatory clinics.

In basic research, we welcomed Dr. Todd Fox and Dr. Danielle Cook and their teams to our Hematology/Oncology Division. We now have a growing team of basic and translational investigators as part of our UVA Cancer Center led by Dr. Tom Loughran. Our Translational Orphan Blood Cancer Research Initiative (TOBRI) led by Dr. Owen O’Connor studies novel treatments for rare blood cancers, including T-cell lymphoma.

In clinical research, we have 78 open clinical research treatment trials. We are grateful to the many friends of the Cancer Center and Hematology/Oncology who provide philanthropic support for our research efforts and also help improve access to clinical trials.

In education, we thank Dr. Rick Hall for the fantastic leadership of our Hematology/Oncology fellowship program. We congratulate Dr. Trish Millard, who will be assuming leadership of our fellowship program in July 2024. Rick has been honored with a new leadership role with the Promotions Committee in the Department of Medicine. In undergraduate medical education, Dr. John Densmore has successfully led the program at Inova, and the students have had another fantastic match year.

We continue to work towards greater engagement with our community and dedication to diversity and equity. It was great to see our team at a Community Service project in the vegetable gardens of Morven Farms.

It is wonderful to have the opportunity to highlight our team’s accomplishments. I am most grateful for the best colleagues ever! We appreciate such fantastic colleagues in other divisions and departments and our wonderful nurses, division staff, research coordinators, and other team members. You all make my job and our vital work so special and fun.

~Karen K. Ballen, MD
DIVISION OF HEMATOLOGY & ONCOLOGY

Disease Updates

Medical Oncology
The medical oncology section concluded a productive clinical and academic year. At the beginning of the new academic year, the section welcomed Dr. Muneeb Rehman, a new GI medical oncologist. After a long search, we have successfully recruited Dr. Ludi Cavalcante to join the Division as the new head of the medical sarcoma program and her role as Associate Director of the Phase I program.

Selected academic highlights include the completion of three investigator-initiated trials in the last year, including the POWER trial led by Dr. Trish Millard, which was presented at the San Antonio Breast Cancer Symposium, the Focused Ultrasound plus pembrolizumab trial (Breast-48) and the Entinostat plus capecitabine trial (Breast-49) led by Dr. Dillon which were also presented at national meetings.

Drs. Ryan Gentzler and Rick Hall were site PIs and co-authors on two separate phase III trials; both presented as late-breaking abstracts in the Presidential Symposium at the European Society of Medical Oncology (ESMO) Congress in Madrid, Spain, in Fall 2023. Dr. Hall was one of the top enrollers on the TROPION-Lung01 trial of datopotamab deruxtecan for second-line metastatic NSCLC presented at the ESMO meeting. Dr. Gentzler was the highest enroller in North America and co-author on the ESMO abstract and simultaneous publication in Annals of Oncology for the MARIPOSA-2 trial of amivantamab plus chemotherapy for EGFR-mutated lung cancer.

Dr. William Skeleton mentored Drs. Soham Ali and Kathryn Fortune both presented posters at the ASCO GU meeting in San Francisco.

~ Robert Dreicer, MD

Melanoma/and related disorders
Drs. Liz Gaughan and Varinder Kaur
APP: Jennifer Eccles, Jenea Brown

Breast Medical Oncology
Drs. Christiana Brenin, Patrick Dillon and Trish Millard
APP: Paul “Mike” Marshall and Melody Noble

Thoracic Medical Oncology
Drs. Ryan Gentzler and Richard Hall
APP: Marie Thomas

Head and Neck Oncology
Dr. Varinder Kaur
APP: Jenea Brown

Gastrointestinal Medical Oncology and Unknown Primary Neoplasms
Drs. Tri Le, Paul Kunk, Muneeb Rehman, and Matthew Reilley
APP: Jenna Ally and Jenna Campo

Genitourinary Medical Oncology
Drs. Michael Devitt, Robert Dreicer, William Paul Skelton, Paul Viscuse
APP: Jennifer Eccles and Katie Stiebing

Sarcoma
Dr. Michael Douvas
Dr. Ludi Cavalcante (joining July 2024)

Infusion/Urgent Care
APP: Elizabeth Coyman, Rachel Chai, and Elizabeth Lester
The Stem Cell Transplant and Cellular Therapy Program continues to grow. We continue to increase our referrals from all over Virginia, including Virginia Beach, Northern Virginia, and Appalachia / SW Virginia. We have two outreach clinics and want to expand our outreach in other areas. We now have patients from different regions, including West Virginia. We perform transplants for various hematologic malignancies, including plasma cell dyscrasias, non-Hodgkin’s lymphoma, Hodgkin lymphoma, acute leukemias, myelodysplastic syndrome, and myeloproliferative disorders, as well as for bone marrow failure states. Our chimeric antigen receptor (CAR) T program is continuing to grow (up more than 25% over the last year), we have access to all FDA approved CART products, and our research CART portfolio continues to grow. We can perform some transplants safely as outpatients. We are a core center with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) to open cooperative group clinical trials at UVA for our patients. We are well represented at the recent Transplant and Cellular Therapy meetings and the American Society of Hematology, with several presentations by our faculty.

~John Wagner, MD

**Hematologic Malignancies**

The Hematologic Malignancy Program continues to grow in patient care and research. We are excited to welcome Dr. Roberts to our lymphoma program this summer. Drs. Ayers, Marchi, Portell, and Williams have had several international presentations on lymphoma. The clinical trial portfolio continues to increase in both B-cell and T-cell lymphoma. Dr. Keng has expanded our quality program, is a global figure in cancer quality, and serves as inpatient medical director. Dr. El Chaer has had several international presentations focusing on measurable residual disease. Dr. El Chaer also serves as the Medical Director of Infusion. Dr. Douvas is an active educator focusing on the complex young adult population. Dr. Garrett-Bakelman is studying epigenetics and older patients with Acute Myeloid Leukemia. In myeloma, Drs. Densmore and Foster are focusing on novel strategies for this population, with many new treatment options for these patients, including cellular and antibody-based therapy.

**Lymphoma and CLL**

Drs. Emily Ayers, Enrica Marchi, Craig Portell, and Michael E. Williams,
Dr. Nate Roberts (joining August 2024)
APP: Kim Conrad

**Myeloma**

Drs. John Densmore and Laahn Foster

**Leukemia**

Drs. Michael Douvas, Firas El Chaer, Francine Garrett-Bakelman, Michael Keng, and Daniel Reed
APP: Kim Conrad and Amelia Hodson
Disease Updates

Classical Hematology

Classical Hematology has had another busy year, particularly in clinical care and education. We manage patients with complex and rare hematologic disorders and are the primary academic referral center for much of Virginia and surrounding states. As classical hematology topics span nearly all other medical and surgical specialties, we remain busy with lectures and conferences to educate medical students, residents, fellows, and other divisions and departments.

Dr. Louise Man continues to direct the grant-supported Adult Comprehensive Hemophilia Treatment Center in conjunction with colleagues in pediatrics. Dr. Davidson leads our Adult Sickle Cell Disorders program and collaborates with SCD centers around the Commonwealth to improve access to comprehensive care and raise awareness for sickle cell disease. Dr. Davidson recently attended the American Society of Hematology’s Advocacy Leadership Institute, advocating for increased funding to support sickle cell disease on Capitol Hill. In conjunction with cardiothoracic surgery, we instituted a peri-operative anemia program to manage iron deficiency in patients undergoing cardiothoracic surgery. We will expand this initiative to other surgeries with high-volume blood loss soon. Dr. Maitland continues her vital work to reduce peri-operative VTE at UVA by improving patient education and mobility. We look forward to adding two new physicians to our group in the coming year.

~Kelly Davidson, MD

Classical Hematology
Drs. Kelly Davidson, Valery Kogler, Hillary Maitland, and Louise Man
APP: Julie Armatas and Katie Gabler

UVA Community Oncology

The UVA Community Oncology Section serves patients in Fishersville and Culpeper with a spectrum of hematologic and solid tumor diagnoses. Our team oversees the multidisciplinary infusion centers at each location. The last year has seen rapid growth of clinical volumes, investments in staff expansion to maximize the use of existing space, and further alignment and integration between the community practices, medical center teams, and the academic Division. Our success in maintaining patient access for both clinic and infusion results from patient-focused teamwork, incorporation of technology, innovative problem solving, and strong relationships within the Oncology service line.

In the last year, the vault for the new linear accelerator in Culpeper was completed. Our northern oncology team is an anchor for Culpeper cancer services, and our providers are leaders on the Culpeper Medical Staff. Dr. Patel and Dr. Mahjoub piloted a successful initiative to precisely align with specific disease teams (Thoracic Oncology and Breast Oncology) at the main campus. Cancer and infusion services continue to grow in the Augusta market.

We look forward to expanding our clinical, infusion and laboratory footprint into the newly vacated space in the building. Several surgical subspecialty teams see patients in our Augusta clinic as our team works to maximize telemedicine connections to Charlottesville. This technological framework will facilitate cancer care closer to home.

~Elizabeth Gaughan, MD

Augusta Location
Drs. Gwenalyn Garcia, Nicholas Paphitis, and Mary Helen Witt

Culpeper Location
Drs. Ali Mahjoub, Pranav Patel, and Balraj Singh
APP: Michelle Otto

Charlottesville/Pantops Location
APP: Susie Herndon

Prince William/Manassas Location
Dr. Balraj Singh
Advance Practice Providers

The APP team continues to work on template optimization with the One Access team and utilization throughout the Division. Expanding on educational opportunities by and for APPs and nursing through the educational series.

• **Education Series**
  - A monthly, topical, lunchtime continuing education series by and for APPs and our nursing colleagues led by Jenna Campo, Rachel Chai, Julie Costin, Dr. Varinder Kaur, Marie Thomas, and Tanya Thomas. Sample presentations last year included Oncologic Emergencies by Amelia Hodson, Medical Cannabis by Jenna Campo and Jenna Ally, and Sickle Cell Anemia by Katie Gabler.

• **We have grown tremendously across the Division, welcoming many new APP team members.**
  - Jenea Brown in Head / Neck and Melanoma
  - Elizabeth “Liz” Lester, DNP in the infusion center (Urgent symptom clinic / C.E.R.T)
  - Elizabeth Coyman, FNP in the infusion center (Urgent symptom clinic / C.E.R.T)
  - Scott Cook, NP in Stem Cell Transplant / Cellular Therapy Program (inpatient)
  - Jordyn Sewell, PA in Stem Cell Transplant / Cellular Therapy Program (inpatient)
  - Doctorate in Nursing
  - Jess Kassay-McAllister March 2023
  - Melody Noble December 2023

• **Publications**
  - Jess Kassay-McAllister, DNP published as a co-author in the Journal of Neuro-Oncology for her work in BATs clinical trial with Camilo Fadul and team and awaiting publication in the Oncology Nursing journal of her DNP project highlighting CARTOX APP use in CAR-T therapy.

• **Couric Emergency Response Team (C.E.R.T) was developed and received approval from the resuscitation committee this past fall. We continue to grow the team to provide ACLS care and meet the needs of our higher acuity patients in the Emily Couric (EC4). This APP-led team receives specialized training and will continue to expand to our community sites in the coming years.**

  ~ Jess Kassay-McAllister and Susie Herndon, APP Supervisor

---

**Updates In Hematology Hematologic Malignancies**

**April 12, 2024**
**The Forum Hotel (Kimpton)**
**540 Massie Road, Charlottesville**

This program will explore research and advances in the diagnosis and management of benign hematologic conditions and hematologic malignancies, including indications for novel therapies and use in special populations.

Click for more information and see agenda or go to [www.cmevillage.com](http://www.cmevillage.com)
Clinical Updates
We continue to grow our clinical volumes and move more of our services to outpatient. Clinical Volumes grow yearly in all of our locations.

Clinical Volume Chart FY 2020 - FY 2023

<table>
<thead>
<tr>
<th></th>
<th>FY 2020</th>
<th>FY 2021</th>
<th>FY 2022</th>
<th>FY 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inpatient Attending</td>
<td>13,351</td>
<td>14,182</td>
<td>14,066</td>
<td>13,898</td>
</tr>
<tr>
<td>Inpatient Consults</td>
<td>2,700</td>
<td>2,733</td>
<td>2,546</td>
<td>2,181</td>
</tr>
<tr>
<td>Inpatient Totals</td>
<td>16,051</td>
<td>16,915</td>
<td>16,612</td>
<td>16,079</td>
</tr>
<tr>
<td>Outpatient New and Consults</td>
<td>4,125</td>
<td>4,611</td>
<td>5,257</td>
<td>5,753</td>
</tr>
<tr>
<td>Established Outpatient Visits</td>
<td>40,721</td>
<td>43,876</td>
<td>47,646</td>
<td>53,846</td>
</tr>
<tr>
<td>Outpatient Totals</td>
<td>44,846</td>
<td>48,487</td>
<td>52,903</td>
<td>59,599</td>
</tr>
</tbody>
</table>

2023 Clinical Faculty Promotions

Dr. David Feith, promoted to Professor
Dr. Paul Kunk, promoted to Associate Professor
Dr. Louise Man, promoted to Associate Professor
Dr. Matthew Reilley, promoted to Associate Professor

HEMATOLOGY/ONCOLOGY GRAND ROUNDS
First Wednesday each Month, 8 - 9am
Via Zoom
Educational Updates

Letter from the Program Director

We are fortunate to have an outstanding Hematology/Oncology fellowship program at the University of Virginia. Our strength lies principally in our people – first and foremost, our dedicated, thoughtful, collegial, and hard–working fellows, our outstanding program coordinator Lisa Mackey, and our committed faculty leaders.

After six years of leading our fellowship program, I will be stepping back into a supporting role as Associate Program Director (APD) while Trish Millard, MD takes over as fellowship program director in July 2024. Trish has established herself as an education leader at UVA – from residency, chief residency, fellowship, and APD of our fellowship since 2019. She will continue to grow our national presence as an education leader. Without a doubt, our program will continue to train Hematology/Oncology physicians who excel in patient care, scholarship, and education under Dr. Millard’s leadership.

~ Richard Hall, MD

Fellowship News

New Fellows

We welcomed four new fellows to the Class of 2026. Below are our first-year fellows with some of their new colleagues from left to right, Nate Roberts MD, Shipra Maheshwari MD, and Phil. Young MD, Sean Dougherty MD (UVA residency), Valerie Tran MD (VCU residency), Gautham Prakash MD (Rush Univ residency), Fabian Bolte MD (UVA residency), and Chris Thomas MBBS.
**Educational Updates**

**Nate Roberts MD**

Nate presented at the prestigious International Conference on Malignant Lymphoma in Lugano, Switzerland, in the summer of 2023. He is pictured (right) with his mentor, Enrica Marchi MD (left).

**Jack Masur MD**

Jack Masur, our 2023 Farrow and Weiss Award recipient, recently presented two posters at the GU-ASCO Annual Meeting in San Francisco, CA. Here pictured with members of the GU oncology team during the meeting (from left to right, Paul Viscuse MD, Soham Ali MD, Paul Skelton MD, Michael Devitt MD, Kathryn Fortune MD, and Jack Masur MD).

**Shipra Maheshwari MD**

Shipra was invited to attend the EGFR Resistors Lung Cancer Conference in the fall of 2023 and presented a project on caring for our EGFR positive lung cancer patients at UVA. Shipra is accompanied by her second-year colleagues at last year’s fellowship graduation (L to R, Jeffrey Lantz DO, Jenna Schleifman MD, Shipra Maheshwari MD, Jack Masur MD).

**Upcoming 2024 Graduations**

We are keeping two graduates nearby and sending two graduates to be near family in Georgia and the Pacific NW. From left to right, Phil Young MD (Kaiser Permanente in Tacoma, WA), Will Thomas MD (Piedmont Cancer Institute in Newnan, GA), Chris Thomas MBBS (Sentara Martha Jefferson Hospital, Charlottesville, VA), and Nate Roberts MD (UVA lymphoma faculty).
Recent Events

Hematology/Oncology Spring Community Day
June 3, 2023, Morven Farms

Drs. Indu Varadarajan, Louise Man, Karen Ballen and Administrator Rachael Boston with their families.

Drs. Indu Varadarajan and Bharadhwaj Kolipakkam.

Dr. Karen Ballen and Dr. Louise Man with her daughter and husband.

UVA Health
Drs. Paul Viscuse and William Skelton.

From left front row: Louise Man, Laahn Foster, Trish Millard, Emily Ayers, Katie Stiebing, Jenna Campo, Francine Garrett-Bakelman, Karen Ballen, Susan Herndon, Marie Thomas, Katie Gabler, Meera Kumar.

From left back row: John Wagner, Mike Keng, Leonid Volodin, Pranav Patel, Paul Viscuse, Melody Noble, Paul Kunk, Jenna Ally, Matt Reilley, Nick Paphitis, Indu Varadarajan, Liz Gaughan

Drs. Richard Hall and Lindsey Taylor (Shantzter), former Heme/Onc fellow.

From left: Mike Keng, Patrick Dillon, Muneeb Rehman, Mike Devitt, Kristine Gillis, Hania Aloul, Gwenalyn Garcia, Craig Portell, Karen Ballen, Jess Kassay-McAllister, Enrica Marchi, Mary Helen Witt, Liz Lester, Firas El Chaer, Tammy Tedsen, Danny Reed, William Skelton, Kim Conrad, Ali Mahjoub, Rachel Chai, Isabel Burgess, Emily Stubbs.

Drs. Andrew Romano (former Heme/Onc fellow), Richard Hall, Mike Devitt, and Ryan Gentzler.
DIVISION OF HEMATOLOGY & ONCOLOGY

San Antonio Breast Cancer Symposium
December 5-9, 2023, San Antonio, Texas

Dr. Lindsey Taylor (Shantzer) former Heme/Onc fellow and Dr. Trish Millard.

The 65th American Society of Hematology Annual Meeting
December 9-12, 2023, San Diego, California

From left front: Drs. Mike Keng, Laahn Foster, Firas El Chaer, Michael E. Williams, Karen Ballen, Leonid Volodin, Indu Varadarajan, Bharadhwaj Kolipakkam. From left back: Drs. David Feith, Emily Ayers, Enrica Marchi, Craig Portell, Kelly Davidson, Nate Roberts.

From left: Drs. Enrica Marchi, Craig Portell, David Feith, Karen Ballen, Firas El Chaer, Michael E. Williams, Kelly Davidson, Nate Roberts, Emily Ayers, Mike Keng, Laahn Foster, Leonid Volodin.

From left: Drs. Indu Varadarajan, Laahn Foster, Nate Roberts, Enrica Marchi, Firas El Chaer, David Feith, Emily Ayers, Craig Portell, Leonid Volodin, Karen Ballen, Kelly Davidson, Michael E. Williams, Mike Keng.

From left: Drs. Patrick Dillon and Trish Millard.

Drs. Patrick Dillon and Trish Millard

Drs. Patrick Dillon and Lindsey Taylor (Shantzer) former Heme/Onc fellow.
DIVISION OF HEMATOLOGY & ONCOLOGY

Transplantation & Cellular Therapy Meeting
February 21-24, 2024, San Antonio, Texas

ASCO Gastrointestinal Cancers Symposium
January 18-20, 2024, San Francisco, California

From left: Judy Kauffman, Glenda Royael, Kathy DeGregory, Brooke Henry, Carly Grubbs, Jessica Brandt

From left: Dr. Matthew Reilley, Dr. Paul Kunk, Jenna Ally, APP, Dr. Tri Le, Dr. Muneeb, Rehman

From left: Margaret (Mimi) Pohl, Taylor Ross, Jenna Van Hoose, Leonid Volodin, Kathy DeGregory, Judy Kauffman, Brooke Henry

From left: Paul Viscuse, Soham Ali, Paul Skelton, Kathryn Fortune, Michael Devitt, Jack Masur

From left: Kathy DeGregory receives the 2024 ASTCT Pharmacy SIG Lifetime Achievement Award surrounded by her colleagues.

CONGRATULATIONS
HEM ONC MATCHES!
Celebrating Excellence!

Above from left:
Enrica Marchi, MD, PhD – Excellence in Research
Indumathy Varadarajan, MD – Excellence in Clinical Care
Kelly Davidson, MD – Diversity, Equity & Inclusion Award

At right: Leonard W. Sandridge Outstanding Contributor Award
This award recognizes outstanding University staff or team members who demonstrate dedication to service through individual efforts, group contributions, and commitment to our larger community. It is the highest individual employee award at the University, named in honor of Leonard W. Sandridge, who was an avid champion of UVA staff and who dedicated 44 years of service to the school. Congratulations to Janet Tillage on this well-deserved honor.

From left: Drs. Nate Roberts, Valerie Tran, Sean Dougherty, Gautham Prakash, Jenna Schlefman, Fabian Bolte and Shipra Maheshwari

From left: Drs. Sean Dougherty, Valerie Tran, Gautham Prakash, and Fabian Bolte

From left: Rachael Boston, Raymond Brown (HR), Nikki Carey, Janet Tillage, Tonia Duncan-Rivers (HR), Lucy Cummings (HR)

From left: Allen Burley, Dr. Trish Millard, Dr. Louise Man, Terri Fisher, Dr. Craig Portell, Rachael Boston, Jennifer Taylor, Janet Tillage, Lisa Mackey, Karen Ballen, Brooke O’Byrne, Jodi Leake, Dr. Patrick Dillon, Nazif Maqani
High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study.


SELECT PUBLICATIONS

DIVISION OF HEMATOLOGY & ONCOLOGY

Trials
Hematology/Oncology faculty serve as PIs on 120 active protocols.

**BREAST**

**A Phase I/II Study of Anti-CD3xAnti-HER2/neu (HER2Bi) Armed Activated T Cells (ATC) and Pembrolizumab Combination Therapy in Women with Metastatic Breast Cancer**

IRB # 19406
CT. Gov. ID: NCT03272334
Sponsor Protocol: Breast 47 BATs
Sponsor: University of Virginia
Principal Investigator: Dillon, Patrick
Study Contact: Ann Brown amb8e@uvahealth.org
Donihee zwz6jm@uvahealth.org 434-243-6377

**A Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer**

IRB # HSR200069
CT. Gov. ID: NCT04090398
Sponsor Protocol: 10302
Sponsor: ETCTN
Principal Investigator: Dillon, Patrick
Study Contact: Olena Glushakova oyg2n@uvahealth.org

**A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator’s Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer**

IRB # HSR220068
CT. Gov. ID: NCT05374512
Sponsor Protocol: TROPION-Breast02
Sponsor: AstraZeneca
Principal Investigator: Dillon, Patrick
Study Contact: Olena Glushakova oyg2n@uvahealth.org

**Clinical Utility of Fluoroestradiol F18 PET/CT in Metastatic Breast Cancer Patients with ER-Positive and HER2-Negative Primary Lesions After Progression on First Line Hormonal Therapy**

IRB # HSR220088
CT. Gov. ID: NCT05068726
Sponsor Protocol: GE-280-401
Sponsor: GE Healthcare, Ltd
Principal Investigator: Brenin, Christiana
Study Contact: Linh-an Cao pbd2am@uvahealth.org 434-297-8785

**CALM: Chronic & Acute Leukemia/MDS & MPN**

**Clinical Utility of Fluoroestradiol F18 PET/CT in Metastatic Breast Cancer Patients with ER-Positive and HER2-Negative Primary Lesions After Progression on First Line Hormonal Therapy**

IRB # HSR220088
CT. Gov. ID: NCT05068726
Sponsor Protocol: GE-280-401
Sponsor: GE Healthcare, Ltd
Principal Investigator: Brenin, Christiana
Study Contact: Linh-an Cao pbd2am@uvahealth.org 434-297-8785

**BREAST**

**A Phase II Study of Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)**

IRB # HSR220277
CT. Gov. ID: NCT05467891
Sponsor Protocol: HCRN BRE20-468 / RaPhLRR
Sponsor: University of Illinois
Principal Investigator: Millard, Trish
Study Contact: Olena Glushakova oyg2n@uvahealth.org

**A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence**

IRB # HSR220393
CT. Gov. ID: NCT05514054
Sponsor Protocol: EMBER-4 / J2J-MC-JZLH
Sponsor: University of Illinois
Principal Investigator: Millard, Trish
Study Contact: Olena Glushakova oyg2n@uvahealth.org

**A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with inoperable locally advanced or metastatic solid tumors**

IRB # HSR2203977
CT. Gov. ID: NCT054925284
Sponsor Protocol: XB002-101
Sponsor: EXELIXIS, Inc.
Principal Investigator: Dreicer, Robert
Study Contact: Kate Skoczylas ks5jk@virginia.edu
Trials

CALM: Chronic & Acute Leukemia/MDS & MPN
Palliative Care Oncology in Relapsed, Refractory, and High-Risk Leukemia Patients: Randomized Phase II Study
IRB # HSR200133
CT. Gov. ID: NCT04482894
Sponsor Protocol: ALeuk 001
Sponsor: University of Virginia
Principal Investigator: El Chaer, Firas
Study Contact: Ann Brown amb8e@uvahealth.org 434-243-9900
Cara Hanby clh5ke@virginia.edu 434-924-7261
Emily Leytham el5mf@virginia.edu 434-924-8709
Jay H Burchard jhb9r@uvahealth.org 434-924-0180
Kim A Bullock kb9d@virginia.edu

A Phase 4, Multi-center Open-label Feasibility Study to Evaluate Outpatient Blinatumomab Administration in Adult Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL) in Complete Hematologic Remission
IRB # HSR200142
CT. Gov. ID: NCT04506086
Sponsor Protocol: 20190014
Sponsor: Amgen
Principal Investigator: Keng, Michael
Study Contact: Cory Caldwell cjc2p@uvahealth.org 434-297-4182

Phase II Trial of Cardioprotective Prophylaxis with Combination of Beta Blocker and Angiotensin-Converting Enzyme Inhibitors During Intensive Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia
IRB # HSR210151
CT. Gov. ID: NCT04977180
Sponsor Protocol: BREAST54
Sponsor: University of Virginia
Principal Investigator: Keng, Michael
Study Contact: Cory Caldwell cjc2p@uvahealth.org 434-297-4182

A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients
IRB # HSR210463
CT. Gov. ID: NCT05284032
Sponsor Protocol: SuppCare 001
Sponsor: University of Virginia
Principal Investigator: El Chaer, Firas
Study Contact: Ann Brown amb8e@uvahealth.org 434-243-9900
Cara Hanby clh5ke@virginia.edu 434-924-7261
Emily Leytham el5mf@virginia.edu 434-924-8709
Jay H Burchard jhb9r@uvahealth.org 434-924-0180
Kim A Bullock kb9d@virginia.edu 434-924-0180

Venetoclax In Combination with ASTX727, an All-ORal TherapY for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY-MDS/MPN): a Randomized, Phase 2 trial
IRB # HSR230204
CT. Gov. ID: NCT04176198
Sponsor Protocol: 10538
Sponsor: ETCTN
Principal Investigator: Reed, Daniel
Study Contact: Cory Caldwell cjc2p@uvahealth.org 434-297-4182
Trials

Cellular Therapies

A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications
IRB # 15670
CT. Gov. ID: NCT01351545
Sponsor Protocol: 10-CBA Unlicensed CVU
Sponsor: National Marrow Donor Program (NMDP)
Principal Investigator: Ballen, Karen
Study Contact: Danyelle Coley jcs6rz@uvahealth.org 434-982-5027

A multicenter safety study of unlicensed, investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients
IRB # 16168
CT. Gov. ID: NCT01656603
Sponsor Protocol: 6637-01 NCBP Unlicensed CVU
Sponsor: National Cord Blood Program
Principal Investigator: Ballen, Karen
Study Contact: Danyelle Coley jcs6rz@uvahealth.org

A Phase I/II Study of Anti-CD3xAnti-HER2/neu (HER2Bi) Armed Activated T Cells (ATC) and Pembrolizumab Combination Therapy in Women with Metastatic Breast Cancer
IRB # 191406
CT. Gov. ID: NCT03272334
Sponsor Protocol: Breast 47 BATs
Sponsor: University of Virginia
Principal Investigator: Dillon, Patrick
Study Contact: Ann Brown amb8e@uvahealth.org
Ashley Donihee zwz6jm@uvahealth.org 434-243-6377

Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis
IRB # 19792
CT. Gov. ID: NCT02934477
Sponsor Protocol: 16-CMS-MF
Sponsor: Center for the International Blood and Marrow Transplant
Principal Investigator: Ballen, Karen
Study Contact: Emily Leytham el5mf@virginia.edu 434-924-7261

Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries with Multiple Myeloma: A Study to Develop Evidence of Effectiveness for the Centers for Medicare and Medicaid Services (CMS)
IRB # 20533
CT. Gov. ID: NCT03127761
Sponsor Protocol: 17-CMS-MM
Sponsor: Center for the International Blood and Marrow Transplant
Principal Investigator: Volodin, Leonid
Study Contact: Emily Leytham el5mf@virginia.edu

Cellular Therapies

Assessment of Allogeneic Hematopoietic Stem Cell Transplantation in Medicare Beneficiaries with Myelodysplastic Syndrome and Related disorders - Part I.
IRB # 20714
CT. Gov. ID:
Sponsor Protocol: 10-CMS-MDS
Sponsor: Center for the International Blood and Marrow Transplant
Principal Investigator: Varadarajan, Indumathy
Study Contact: Emily Leytham el5mf@virginia.edu 434-924-7261

Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or large B-cell lymphoma patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release
IRB # 21445
CT. Gov. ID: NCT03601442
Sponsor Protocol: Kymriah_CCTL019B2003I
Sponsor: Novartis
Principal Investigator: Varadarajan, Indumathy
Study Contact: Danyelle Coley jcs6rz@uvahealth.org 434-982-5027

Long G-Term Follow-Up Protocol for Subjects Treated with Gene-Modified T-Cells
IRB # HSR200219
CT. Gov. ID: NCT03435796
Sponsor Protocol: GC-LTFU-001
Sponsor: Celgene
Principal Investigator: Varadarajan, Indumathy
Study Contact: Ann Brown amb8e@uvahealth.org
Jay H Burchard jhb9r@uvahealth.org 434-924-8709
Kim A Bullock kb9d@virginia.edu 434-924-0180

A multi-center, phase II trial of HLA-mismatched unrelated donor hematopoietic cell transplantation with post-transplantation cyclophosphamide for patients with hematologic malignancies
IRB # HSR210160
CT. Gov. ID: NCT04904588
Sponsor Protocol: ACCESS
Sponsor: National Marrow Donor Program (NMDP)
Principal Investigator: Ballen, Karen
Study Contact: Emily Leytham el5mf@virginia.edu 434-924-7261

Phase I Study of Tagraxofusp for Post-Transplant Maintenance for Patients with CD 123+ Acute Myeloid Leukemia, Myelofibrosis and Chronic Myelomonocytic Leukemia
IRB # HSR210434
CT. Gov. ID: NCT05233618
Sponsor Protocol: HSR210434
Sponsor: University of Virginia
Principal Investigator: Ballen, Karen
Study Contact: Ann Brown amb8e@uvahealth.org
Cara Hanby clh5ke@virginia.edu 434-243-9900
Jay H Burchard jhb9r@uvahealth.org 434-924-8709
Kim A Bullock kb9d@virginia.edu 434-924-0180
Trials

**Cellular Therapies**

*A Phase 2/3, Multicenter, randomized, Double-blind, placebo-controlled, study to evaluate the safety and efficacy of Alpha-1 Antitrypsin for the prevention of graft-versus-host disease in patients receiving hematopoietic cell transplant (MODULAAE Study)*

IRB # 15670
CT. Gov. ID: NCT03805789
Sponsor Protocol: CSL964_2001
Sponsor: CSL Behring, LLC
Principal Investigator: Volodin, Leonid
Study Contact: Danyelle Coley jcs6rz@uvahealth.org
434-982-5027

*A phase 3 randomized study comparing bortezomib, lenalidomide and dexamethasone (VRd) followed by ciltaacetabtagene autoleucel, a chimeric antigen receptor T cell (CAR-T) Therapy directed against CMA versus bortezomib, lenalidomide, and dexamethasone (VRd) followed by lenalidomide and dexamethasone (RD therapy in patients with newly diagnosed multiple myeloma for who hematopoietic stem cell transplant is not planned as initial therapy*

IRB # 16168
CT. Gov. ID: NCT04925284
Sponsor Protocol: 68284528MMY3004
Sponsor: Janssen Research & Development
Principal Investigator: Foster, Laahn
Study Contact: Sara Casana Granell qna7wg@uvahealth.org 434-924-5254

*A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation*

IRB # HSR230345
CT. Gov. ID: NCT06001385
Sponsor Protocol: OPTIMIZE
Sponsor: Center for the International Blood and Marrow Transplant Principal Investigator: Ballen, Karen
Study Contact: Eva Forman stw7ak@uvahealth.org

**Developmental Therapeutics**

*A phase 1/1b dose escalation and cohort expansion study of MGC018 in combination with MGD019 in participants with advanced solid tumors*

IRB # HSR220272
CT. Gov. ID: NCT05293496
Sponsor Protocol: CP-MGC018-02
Sponsor: MacroGenics, Inc.
Principal Investigator: Reilley, Matthew
Study Contact: Francis Bagley fb9up@uvahealth.org

*A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with inoperable locally advanced or metastatic solid tumors*

IRB # HSR220397
CT. Gov. ID: NCT04925284
Sponsor Protocol: XBO02-101
Sponsor: EXELIXIS, Inc.
Principal Investigator: Dreicer, Robert
Study Contact: Kate Skoczylas ks5jk@virginia.edu

*A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-333 in Adult Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors*

IRB # HSR230073
CT. Gov. ID: NCT05225584
Sponsor Protocol: Kymera Therapeutics, Inc.
Sponsor: Celgene
Principal Investigator: Marchi, Enrica
Study Contact: DeJuana Coleman evq9yw@uvahealth.org 434-924-9199

*A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors*

IRB # HSR230092
CT. Gov. ID: NCT05176483
Sponsor Protocol: XL092-002 / STELLAR-002
Sponsor: EXELIXIS, Inc
Principal Investigator: Dreicer, Robert
Study Contact: Alexandra Cash aec5gn@uvahealth.org 434-243-4305

*A First-in-Human, Phase 1a/1b, Open-Label, Dose-Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of the RAF Dimer Inhibitor BGB-3245 in Patients with Advanced or Refractory Tumors*

IRB # HSR230149
CT. Gov. ID: NCT04249843
Sponsor Protocol: BGB-3245-AU-001
Sponsor: MapKure, LLC
Principal Investigator: Gaughan, Elizabeth
Study Contact: Samantha Schaeffer sms6wn@uvahealth.org

434-297-5588
Trials

Developmental Therapeutics

A First-in-Human, Phase 1a/1b, Open-Label, Dose-Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of the RAF Dimer Inhibitor BGB-3245 in Patients with Advanced or Refractory Tumors
IRB # HSR230149
CT. Gov. ID: NCT04249843
Sponsor Protocol: BGB-3245-AU-001
Sponsor: MapKure, LLC
Principal Investigator: Gaughan, Elizabeth
Study Contact: Samantha Schaeffer sms6wn@uvahealth.org

Gastro-intestinal (GI)

A phase 1b/2, master protocol evaluating the safety, tolerability, pharmacokinetics, and efficacy of sotarasib (AMG 510) in subjects with advanced solid tumors with KRAS p.G12C Mutation
IRB # HSR220237
CT. Gov. ID: NCT05293496
Sponsor Protocol: 20190135
Sponsor: Amgen
Principal Investigator: Gentzler, Ryan
Study Contact: Lacey N Garrett lb5tu@uvahealth.org 434-297-5588

A phase 1b/1b dose escalation and cohort expansion study of MGC018 in combination with MGD019 in participants with advanced solid tumors
IRB # HSR220227
CT. Gov. ID: NCT05293496
Sponsor Protocol: CP-MGC018-02
Sponsor: MacroGenics, Inc.
Principal Investigator: Reilley, Matthew
Study Contact: Francis Bagley fb9up@uvahealth.org

A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with inoperable locally advanced or metastatic solid tumors
IRB # HSR220397
CT. Gov. ID: NCT04925284
Sponsor Protocol: XB002-101
Sponsor: EXELIXIS, Inc.
Principal Investigator: Dreicer, Robert
Study Contact: Kate Skoczylas ks5jk@virginia.edu

GenitoUrinary (GU)

Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN)
IRB # 19690
CT. Gov. ID: NCT03151629
Sponsor Protocol: c16-170
Sponsor: Cancer Clinical Trials Consortium, LLC
Principal Investigator: Dreicer, Robert
Study Contact: Emily Leytham el5mf@virginia.edu 434-924-7261

A Phase Ib/II Study of Intermittent Talazoparib Plus Temozolomide in Subjects with Metastatic Castration Resistant Prostate Cancer and No Mutations in DNA Damage Repair
IRB # 21826
CT. Gov. ID: NCT04019327
Sponsor Protocol: C18-205
Sponsor: Memorial Sloan-Kettering Cancer Center
Principal Investigator: Devitt, Michael
Study Contact: Christine Martin cmp2p@uvahealth.org

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors
IRB # HSR230092
CT. Gov. ID: NCT05176483
Sponsor Protocol: XL092-002 / STELLAR-002
Sponsor: EXELIXIS, Inc.
Principal Investigator: Dreicer, Robert
Study Contact: Alexandra Cash aec5gn@uvahealth.org 434-243-4305

Gastro-intestinal (GI)

A First-in-Human, Phase 1a/1b, Open-Label, Dose-Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of the RAF Dimer Inhibitor BGB-3245 in Patients with Advanced or Refractory Tumors
IRB # HSR230149
CT. Gov. ID: NCT04249843
Sponsor Protocol: BGB-3245-AU-001
Sponsor: MapKure, LLC
Principal Investigator: Gaughan, Elizabeth
Study Contact: Samantha Schaeffer sms6wn@uvahealth.org

A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinitib versus Physician’s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR) altered, Chemotherapy-and FGFR Inhibitor Refractory/Relapsed Cholangiocarcinoma (FIRST-308)
IRB # HSR230329
CT. Gov. ID: NCT05948475
Sponsor Protocol: TT420C2308 / FIRST-308
Sponsor: TransThera Sciences (Nanjing), Inc.
Principal Investigator: Kunk, Paul
Study Contact: Kristen A Harris kah2gv@uvahealth.org 434-297-5724

A Phase Ib/II Study of Intermittent Talazoparib Plus Temozolomide in Subjects with Metastatic Castration Resistant Prostate Cancer and No Mutations in DNA Damage Repair
IRB # 21826
CT. Gov. ID: NCT04019327
Sponsor Protocol: C18-205
Sponsor: Memorial Sloan-Kettering Cancer Center
Principal Investigator: Devitt, Michael
Study Contact: Christine Martin cmp2p@uvahealth.org

A Phase II Open-Label, Study of 1MMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy
IRB # HSR210450
CT. Gov. ID: NCT03547973
Sponsor Protocol: 1MMU-132-06
Sponsor: Gilead Sciences, Inc.
Principal Investigator: Dreicer, Robert
Study Contact: Christine Martin cmp2p@uvahealth.org
DIVISION OF HEMATOLOGY & ONCOLOGY

**Trials**

### Gastro-intestinal (GI)

**A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 in Patients with Metastatic Castration-Resistant Prostate Cancer**

IRB # HSR220523  
CT. Gov. ID: NCT05067140  
Sponsor: Arvinas, Inc.  
Principal Investigator: Dreicer, Robert  
Study Contact: Jasmine Lu jl2bw@uvahealth.org

**A Phase 2 Trial to Evaluate the Safety and Efficacy of NKT2152 in Combination with Palbociclib (Doublet) and with Palbociclib and Sasanlimab (Triplet) in Patients with Advanced or Metastatic Renal Clear Cell Carcinoma**

IRB # HSR220311  
CT. Gov. ID: NCT05935748  
Sponsor: NiKang Therapeutics, Inc.  
Principal Investigator: Dreicer, Robert  
Study Contact: Steven H Goff wrs9hw@uvahealth.org

**A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with inoperable locally advanced or metastatic solid tumors**

IRB # HSR220397  
CT. Gov. ID: NCT04925284  
Sponsor: EXELIXIS, Inc.  
Principal Investigator: Dreicer, Robert  
Study Contact: Kate Skoczylas ks5jk@virginia.edu

**A Phase 1/2 study of lorigerlimab with Docetaxel or Docetaxel Alone in Participants with Metastatic Castration-Resistant Prostate Cancer**

IRB # HSR230238  
CT. Gov. ID: NCT05848011  
Sponsor Protocol: CP-MGD019-02  
Sponsor: MacroGenics, Inc  
Principal Investigator: Skelton, William  
Study Contact: Christine Martin cmp2p@uvahealth.org

**A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors**

IRB # HSR230092  
CT. Gov. ID: NCT05176483  
Sponsor Protocol: XL092-002 / STELLAR-002  
Sponsor: EXELIXIS, Inc.  
Principal Investigator: Dreicer, Robert  
Study Contact: Alexandra Cash aec5gn@uvahealth.org

**A Phase 2, Randomized, Open-Label, Study of Lorigerlimab with Docetaxel or Docetaxel Alone in Participants with Metastatic Castration-Resistant Prostate Cancer**

IRB # HSR230238  
CT. Gov. ID: NCT05848011  
Sponsor Protocol: CP-MGD019-02  
Sponsor: MacroGenics, Inc  
Principal Investigator: Skelton, William  
Study Contact: Christine Martin cmp2p@uvahealth.org

### Head & Neck

**Phase 1-2 study investigating safety, tolerability, pharmacokinetics and preliminary antitumor activity of anti-TIM-3-Monoclonal antibody BGB-A425 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in patients with advanced solid tumors**

IRB # HSR220014  
CT. Gov. ID: NCT03744468  
Sponsor: BeiGene, Ltd.  
Principal Investigator: Kaur, Varinder  
Study Contact: Olusegun Adelaja oba4e@uvahealth.org

**A Phase 1/1b Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer**

IRB # HSR220202  
CT. Gov. ID: NCT05172245  
Sponsor Protocol: 10492  
Sponsor: ETCTN  
Principal Investigator: Kaur, Varinder  
Study Contact: Olusegun Adelaja oba4e@uvahealth.org

### Gastro-intestinal (GI)

**A Phase 2, Randomized, Open-Label, Study of Lorigerlimab with Docetaxel or Docetaxel Alone in Participants with Metastatic Castration-Resistant Prostate Cancer**

IRB # HSR230238  
CT. Gov. ID: NCT05848011  
Sponsor Protocol: CP-MGD019-02  
Sponsor: MacroGenics, Inc  
Principal Investigator: Skelton, William  
Study Contact: Christine Martin cmp2p@uvahealth.org

**A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with inoperable locally advanced or metastatic solid tumors**

IRB # HSR220397  
CT. Gov. ID: NCT04925284  
Sponsor: EXELIXIS, Inc.  
Principal Investigator: Dreicer, Robert  
Study Contact: Kate Skoczylas ks5jk@virginia.edu

**A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors**

IRB # HSR230092  
CT. Gov. ID: NCT05176483  
Sponsor Protocol: XL092-002 / STELLAR-002  
Sponsor: EXELIXIS, Inc.  
Principal Investigator: Dreicer, Robert  
Study Contact: Alexandra Cash aec5gn@uvahealth.org

**A Phase 1/2 study investigating safety, tolerability, pharmacokinetics and preliminary antitumor activity of anti-TIM-3-Monoclonal antibody BGB-A425 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in patients with advanced solid tumors**

IRB # HSR220014  
CT. Gov. ID: NCT03744468  
Sponsor: BeiGene, Ltd.  
Principal Investigator: Kaur, Varinder  
Study Contact: Olusegun Adelaja oba4e@uvahealth.org

**A Phase 1/1b Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer**

IRB # HSR220202  
CT. Gov. ID: NCT05172245  
Sponsor Protocol: 10492  
Sponsor: ETCTN  
Principal Investigator: Kaur, Varinder  
Study Contact: Olusegun Adelaja oba4e@uvahealth.org
Trials

Head & Neck

A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination with INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants with PD-LI-Positive (CPS &≥805; 1) Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

IRB # HSR2200252
CT. Gov. ID: NCT05287113
Sponsor Protocol: INCAGN 2385-203
Sponsor: Incyte Corporation
Principal Investigator: Kaur, Varinder
Study Contact: Zoe Hemmer zh7jf@virginia.edu

Lymphoma

A Phase III/I/II randomized study of R-miniCHOP with or without oral azacitidine (CC-436) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIb Follicular Lymphoma, transformed lymphoma, and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements

IRB # HSR210225
CT. Gov. ID: NCT04799275
Sponsor Protocol: S1918
Sponsor: SWOG
Principal Investigator: Ayers, Emily
Study Contact: Study Contact: Erica Stallard elg9r@uvahealth.org 434-243-2649

A phase Ib open-label study to evaluate the safety and anti-cancer activity of loncastuximab terisine in combination with other anti-cancer agents in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

IRB # HSR220009
CT. Gov. ID: NCT04970901
Sponsor Protocol: ADCT-402-105
Sponsor: ADC Therapeutics S.A.
Principal Investigator: Ayers, Emily
Study Contact: Michal Ande mma2cz@uvahealth.org

MAJIC: A Phase III Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib plus Venetoclax versus Venetoclax plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

IRB # HSR220204
CT. Gov. ID: NCT03547973
Sponsor Protocol: D8220C00027
Sponsor: AstraZeneca
Principal Investigator: Portell, Craig
Study Contact: Michal Ande mma2cz@uvahealth.org

A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)

IRB # HSR220402
CT. Gov. ID: NCT04965493
Sponsor Protocol: LOXO-BTK-20022 (J2N-OX-JZ
Sponsor: Eli Lilly
Principal Investigator: Ayers, Emily
Study Contact: Naomi Spencer jre8qk@uvahealth.org
Trials

**Lymphoma**

*Pembrolizumab-based adaptive therapy for classical Hodgkin lymphoma in patients age 60 and above*

IRB # HSR210534
CT. Gov. ID: NCT05404945
Sponsor Protocol: CHL001
Sponsor: University of Virginia
Principal Investigator: Portell, Craig
Study Contact: Ann Brown amb8e@uvahealth.org
Cara Hanby clh5ke@virginia.edu
Jay H Burchard jhb9r@uvahealth.org
Jennifer L Garth jlg8tg@uvahealth.org
Kim A Bullock kb9d@virginia.edu

*A First-in-Human, Phase 1a/1b, Open-Label, Dose-Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of the RAF Dimer Inhibitor BGB-3245 in Patients with Advanced or Refractory Tumors*

IRB # HSR230149
CT. Gov. ID: NCT04249843
Sponsor Protocol: BGB-3245-AU-001
Sponsor: MapKure, LLC
Principal Investigator: Gaughan, Elizabeth
Study Contact: Samantha Schaeffer sms6wn@uvahealth.org

**PBT: Plasma/Benign/T-Cell**

*A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin versus Investigator’s Choice in Patients with Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)*

IRB # HSR200080
CT. Gov. ID: NCT04747236
Sponsor Protocol: PTCL-001
Sponsor: University of Virginia
Principal Investigator: Marchi, Enrica
Study Contact: Aishling Rada jdp5pg@uvahealth.org
Ann Brown amb8e@uvahealth.org
Cara Hanby clh5ke@virginia.edu 434-243-9900
Jay H Burchard jhb9r@uvahealth.org 434-924-8709
Kim A Bullock kb9d@virginia.edu 434-924-0180

**A Phase 3 Trial of Fianlimab (anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients with Completely Resected High-Risk Melanoma (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended For Early Autologous Transplantation**

IRB # HSR210057
CT. Gov. ID: NCT04566328
Sponsor Protocol: EAA181
Sponsor: ECOG-ACRIN
Principal Investigator: Foster, Laahn
Study Contact: Aishling Rada jdp5pg@uvahealth.org
434-924-0816

A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma

IRB # 21772
CT. Gov. ID: NCT03969004
Sponsor Protocol: R2810-ONC-1788
Sponsor: Regeneron Pharmaceuticals, Inc.
Principal Investigator: Kaur, Varinder
Study Contact: Samantha Schaeffer sms6wn@uvahealth.org
434-243-2649

A First-in-Human, Phase 1a/1b, Open-Label, Dose-Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of the RAF Dimer Inhibitor BGB-3245 in Patients with Advanced or Refractory Tumors

IRB # HSR230149
CT. Gov. ID: NCT04249843
Sponsor Protocol: BGB-3245-AU-001
Sponsor: MapKure, LLC
Principal Investigator: Gaughan, Elizabeth
Study Contact: Samantha Schaeffer sms6wn@uvahealth.org

**Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination with CMP-001 in Patients with Operable Melanoma: Efficacy and Biomarker Study**

IRB # HSR210158
CT. Gov. ID: NCT04708418
Sponsor Protocol: EA6194
Sponsor: ECOG-ACRIN
Principal Investigator: Gaughan, Elizabeth
Study Contact: Samantha Schaeffer sms6wn@uvahealth.org
434-243-2649

**A First-in-Human, Phase 1a/1b, Open-Label, Dose-Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of the RAF Dimer Inhibitor BGB-3245 in Patients with Advanced or Refractory Tumors**

IRB # HSR230149
CT. Gov. ID: NCT04249843
Sponsor Protocol: BGB-3245-AU-001
Sponsor: MapKure, LLC
Principal Investigator: Gaughan, Elizabeth
Study Contact: Samantha Schaeffer sms6wn@uvahealth.org

**A Phase 3 Trial of Fianlimab (anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients with Completely Resected High-Risk Melanoma**

IRB # HSR220467
CT. Gov. ID: NCT05608291
Sponsor Protocol: R3767-ONC-2055
Sponsor: Regeneron Pharmaceuticals, Inc.
Principal Investigator: Gaughan, Elizabeth
Study Contact: Rachael L Zhang rlz4fp@virginia.edu
571-699-6379

**Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended For Early Autologous Transplantation**

IRB # HSR210057
CT. Gov. ID: NCT04566328
Sponsor Protocol: EAA181
Sponsor: ECOG-ACRIN
Principal Investigator: Foster, Laahn
Study Contact: Aishling Rada jdp5pg@uvahealth.org
434-924-0816
Trials

**PBT: Plasma/Benign/T-Cell**

**Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)**

IRB # HSR200035
CT. Gov. ID: NCT03937635
Sponsor Protocol: EAA173
Sponsor: ECOG-ACRIN
Principal Investigator: Foster, Laahn
Study Contact: Aishling Rada  jdp5pg@uvahealth.org 434-924-0816

"A phase 3 randomized study comparing bortezomib, lenalidomide and dexamethasone (VRd) followed by ciltacabtagene autoleucel, a chimeric antigen receptor T cell (CAR-T) Therapy directed against CMA versus bortezomib, lenalidomide, and dexamethasone (VRd) followed by lenalidomide and dexamethasone (RD therapy in patients with newly diagnosed multiple myeloma for who hematopoietic stem cell transplant is not planned as initial therapy"

IRB # HSR220093
CT. Gov. ID: NCT04923893
Sponsor Protocol: 6824528MMY3004
Sponsor: Janssen Research & Development
Principal Investigator: Foster, Laahn
Study Contact: Sara Casana Granell qna7wg@uvahealth.org 434-924-5254

**A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects with Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas**

IRB # HSR220315
CT. Gov. ID: NCT05475925
Sponsor: Dren Bio, Inc
Principal Investigator: Marchi, Enrica
Study Contact: Aishling Rada  jdp5pg@uvahealth.org 434-924-5254

**A Phase 1/1a Study of Venetoclax, MLN9708 (ixazomib citrate) and Dexamethasone for Relapsed/Refractory Light Chain Amyloidosis**

IRB # HSR220316
CT. Gov. ID: NCT04847453
Sponsor: ETCTN
Principal Investigator: Foster, Laahn
Study Contact: Alexandra Cash aec5gn@uvahealth.org 434-243-4305

"A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-333 in Adult Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors"

IRB # HSR230073
CT. Gov. ID: NCT05225584
Sponsor Protocol: KT333-TL-101
Sponsor: Kymera Therapeutics, Inc.
Principal Investigator: Marchi, Enrica
Study Contact: DeJuana Coleman evq9yw@uvahealth.org 434-924-9199

**PBT: Plasma/Benign/T-Cell**

"A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy"

IRB # HSR230148
CT. Gov. ID: NCT05455320
Sponsor Protocol: 64407564MMY3002
Sponsor: Janssen Research & Development
Principal Investigator: Foster, Laahn
Study Contact: Theressa Leak tol3w@uvahealth.org 434-243-4308

**Thoracic**

**Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)**

IRB # 17719
CT. Gov. ID: NCT02194738
Sponsor Protocol: A151216
Sponsor: ECOG-ACRIN
Principal Investigator: Hall, Richard
Study Contact: Lacey N Garrett  lb5tu@uvahealth.org 434-297-5588

"A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein"

IRB # 17721
CT. Gov. ID: NCT02201992
Sponsor Protocol: E4512
Sponsor: ECOG-ACRIN
Principal Investigator: Hall, Richard
Study Contact: Gracie Hockenberry mgt4n@virginia.edu 434-297-7784

"Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR"

IRB # HSR220009
CT. Gov. ID: NCT03191149
Sponsor Protocol: EA5162
Sponsor: ECOG-ACRIN
Principal Investigator: Hall, Richard
Study Contact: Gracie Hockenberry mgt4n@virginia.edu 434-297-7784

"An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naive EGFR-mutant Locally Advanced or Metastatic NSCLC"

IRB # HSR200034
CT. Gov. ID: NCT03909334
Sponsor Protocol: LUN18-335
Sponsor: MD Anderson CC
Principal Investigator: Hall, Richard
Study Contact: Gracie Hockenberry mgt4n@virginia.edu 434-297-7784
**Trials**

**Thoracic**

---

**ETCTN10216: A Phase I/II Study of AZD9291 and CB-839 HCl in Patients with EGFR Mutant Non-Small Cell Lung Cancer**

IRB # HSR200081  
CT. Gov. ID: NCT03831932  
Sponsor Protocol: ETCTN10216  
Sponsor: ETCTN  
Principal Investigator: Hall, Richard  
Study Contact: Lacey N Garrett lb5tu@uvahealth.org  
434-297-5588

**Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC**

IRB # HSR200159  
CT. Gov. ID: NCT04092283  
Sponsor Protocol: EA5181  
Sponsor: ECOG-ACRIN  
Principal Investigator: Hall, Richard  
Study Contact: Yaroslav Shvorak ys7cb@uvahealth.org  
434-297-7384

**A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm**

IRB # HSR200297  
CT. Gov. ID: NCT04317534  
Sponsor Protocol: LUN18-153  
Sponsor: Big Ten Cancer Research Consortium  
Principal Investigator: Hall, Richard  
Study Contact: Gracie Hockenberry mgt4n@virginia.edu  
434-297-7784

**A phase II study of adjuvant treatment with cisplatin-based chemotherapy plus concomitant atezolizumab in patients with stage I (tumors= 4cm), IIA, IIB, and select stage III [any T1-3, N1-2, and T4N0-2] resected non-small cell lung cancer (NSCLC) and the clearance of circulating tumor DNA (ctDNA) Big Ten Cancer Research Consortium BTCRC-LUN19-1976**

IRB # HSR210517  
CT. Gov. ID: NCT04367311  
Sponsor Protocol: BTCRC-LUN19-396  
Sponsor: Big Ten Cancer Research Consortium  
Principal Investigator: Hall, Richard  
Study Contact: Gracie Hockenberry mgt4n@virginia.edu  
434-297-7784

**A phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancer**

IRB # HSR230051  
CT. Gov. ID: NCT05617313  
Sponsor Protocol: LUN21-497  
Sponsor: Hoosier Cancer Research Network  
Principal Investigator: Gentzler, Ryan  
Study Contact: Gracie Hockenberry mgt4n@virginia.edu  
434-297-7784

**A Phase I, Open-label, Multicenter, Dose Escalation and Cohort Expansion Study of SPYK04 as Monotherapy in Patients with Locally Advanced or Metastatic Solid Tumors**

IRB # HSR220309  
CT. Gov. ID: NCT04511845  
Sponsor Protocol: SPK101JG  
Sponsor: Chugai Biopharmaceuticals  
Principal Investigator: Gentzler, Ryan  
Study Contact: Gracie Hockenberry mgt4n@virginia.edu

---

**Thoracic**

---

**A Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy (PACIFIC-9)**

IRB # HSR220031  
CT. Gov. ID: NCT05221840  
Sponsor Protocol: D9078C00001  
Sponsor: AstraZeneca  
Principal Investigator: Gentzler, Ryan  
Study Contact: Gracie Hockenberry mgt4n@virginia.edu  
434-297-7784

**A phase 3, randomized, double-blind study of MK-7684A in combination with etoposide and platinum followed by MK-7684A vs. atezolizumab in combination with etoposide and platinum followed by atezolizumab for the first-line treatment of participants with extensive stage small cell lung cancer**

IRB # HSR220218  
CT. Gov. ID: NCT05224141  
Sponsor Protocol: 008-01  
Sponsor: Merck Sharp & Dohme Corp.  
Principal Investigator: Hall, Richard  
Study Contact: Gracie Hockenberry mgt4n@virginia.edu

**A phase 1b/2, master protocol evaluating the safety, tolerability, pharmacokinetics, and efficacy of sotarasib (AMG 510) in subjects with advanced solid tumors with KRAS p.G12C Mutation**

IRB # HSR220237  
CT. Gov. ID: NCT04185883  
Sponsor Protocol: 20190135  
Sponsor: Amgen  
Principal Investigator: Gentzler, Ryan  
Study Contact: Lacey Garrett lb5tu@uvahealth.org  
434-297-5588

**A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with inoperable locally advanced or metastatic solid tumors**

IRB # HSR220397  
CT. Gov. ID: NCT04925284  
Sponsor Protocol: XB002-101  
Sponsor: EXELIXIS, Inc.  
Principal Investigator: Dreicer, Robert  
Study Contact: Kate Skoczylas ks5jk@virginia.edu
Trials

Thoracic

A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
IRB # HSR230066
CT. Gov. ID: NCT03831932
Sponsor Protocol: DZ2022E0005
Sponsor: Dizal Pharmaceutical Co., Ltd
Principal Investigator: Gentzler, Ryan
Study Contact: Gracie Hockenberry mgt4n@virginia.edu
434-297-7784

A randomized, double-blind phase 2/3 study of Fianlimab (anti-lag 3 antibody), Cemiplimab (anti-pd-1 antibody), and chemotherapy versus cemiplimab and chemotherapy in first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) irrespective of PD-L1 expression levels.
IRB # HSR230219
CT. Gov. ID: NCT05800015
Sponsor Protocol: R3767-ONC-2236
Sponsor: Regeneron Pharmaceuticals, Inc.
Principal Investigator: Hall, Richard
Study Contact: Lacey N Garrett lb5tu@uvahealth.org
434-297-5588

PRAGMATICA - LUNG: A Prospective Randomized Study of ramucirumab (LY3009806; NSC 749128) plus pembrolizumab (MK-3475; NSC 776864) versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
IRB # HSR230068
CT. Gov. ID: NCT05633602
Sponsor Protocol: S2302
Sponsor: SWOG
Principal Investigator: Gentzler, Ryan
Study Contact: Gracie Hockenberry mgt4n@virginia.edu
434-297-7784

A First-in-Human, Phase 1a/1b, Open-Label, Dose-Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of the RAF Dimer Inhibitor BGB-3245 in Patients with Advanced or Refractory Tumors
IRB # HSR230149
CT. Gov. ID: NCT04249843
Sponsor Protocol: BGB-3245-AU-001
Sponsor: MapKure, LLC
Principal Investigator: Gaughan, Elizabeth
Study Contact: Samantha Schaeffer sms6wn@uvahealth.org
434-243-4305

A Phase 2 Study of Alisertib in Patients with Extensive Stage Small Cell Lung Cancer
IRB # HSR230339
CT. Gov. ID: NCT06095505
Sponsor Protocol: PUMA-ALI-4201
Sponsor: Puma Biotechnology, Inc.
Principal Investigator: Gentzler, Ryan
Study Contact: Gracie Hockenberry mgt4n@virginia.edu

Administration News

Nazif Maqani joined Hematology/Oncology on October 9, 2023, as the Senior Finance Generalist. Nazif has worked for the University of Virginia for 21 years, and we are delighted that Nazif has joined our team.
Tell us a little bit about yourself.
I have been at UVA for almost 18 years. I started my career at the University of Virginia as a Research Associate in Molecular Biology and Biological Physics, and my research focus was Protein-Protein Interaction inhibitor development for “undruggable” transcription factors in hematological cancers, specifically inv (16) AML. Before moving to the USA for postdoctoral experience, I gained comprehensive expertise that is critical for small molecule drug development, Organic synthesis of “Heterocyclic” molecules (Ph.D.), “combinatorial and parallel synthesis” (Postdoctoral), and Scale-up (industrial experience). My lab and I currently focus on developing drug delivery nanotechnologies and solutions to molecular (siRNA, mRNAs) and pharmaceutical (small molecules) to improve pharmacokinetics, bioavailability, and toxicological profiles through targeted delivery, precisely epigenetic modulating drugs. In addition, we also “re-formulate” oncological, immunological, neurological, and metabolic drugs to increase and extend IP protection.

Why Research?
Research, especially basic science research, is fundamental to developing healthcare solutions that touch everyone’s lives and improve quality of life. I have always been interested in healthcare and wanted to contribute my efforts toward work that benefits the most people.

What brought you to Charlottesville?
My employment brought me to Charlottesville. My passion for drug development and UVA resources in multidisciplinary academic research entrepreneurship, from innovation to impact, is a foundation for my long-term stay.

What excites you about your work?
Finding new treatments/medicines is hitting a target in the dark. The journey of novel drug discovery is arduous and requires excellent teamwork, perseverance, hard work, and dedication. The payoff of developing a new treatment is exhilarating and beneficial to all.

What do you consider to be your greatest achievement outside the professional realm?
Despite being thousands of miles away, I try to stay connected with my family and offer my support to be together. Family is a smaller version of society and is the most vital part of life. I am grateful to have a loving and supportive one.

Describe yourself in one word.
Resilient.

What do you enjoy doing on the weekend?
My parents and spiritual teacher highly motivated me to teach values, gratitude, humility, and responsibility from childhood while acquiring technical skills that significantly impact a child’s personality development. I serve the community by providing a support system to train kids to gain these moral values and put that knowledge into action to make them outstanding citizens.

How did you meet your partner?
I met my husband, Murali Illendula, through the family network. I wouldn’t be here without his support, courage, and love.

Do you have any pets?
Yes, a lovely Aussiedoodle, Neela. She has been our family’s most adorable, energetic, and loyal addition. We chose her because of my daughter, Meghana Illendula.

What is your favorite vacation/activity?
Spending time with my parents and siblings at my home in India, where I grew up, is my favorite vacation.

Who is the person you admire most, and why?
My father, Dr. Rangaiah Kancharla. He is a veterinarian doctor by training who grew up during India’s post-independence depression period. His significant contributions have strengthened children by providing education, relieving child labor, developing co-ops for farming families, and fighting for farmers’ fair pay policies. He is a bridge between government reforms and people in need. His service is the foundation for my life and current personality. My father’s vision of education, women’s employment, and serving society is the moral pillar for all our siblings’ lives, especially for my Ph.D. My parents provided values of commitment, preservation, and courage to face the challenges.

What is the best advice anyone ever gave you?
“Serve all beings as service to God. Worship your own, and respect all” - My spiritual teacher, HH Sri Chinna Jeeyar Swamy.

Would you rather do one thing extraordinarily well or ten things admirably well?
My scientific training by my Ph.D. mentor, Venkateswarlu Peesapati, and PIs, Professor David W. Boykin, and Professor Mark Kester, and life taught me the incredible skill of doing ten things admirably well. It’s a juggling act, but a focused mind and practice provide this remarkable skill.
Tell us a little bit about yourself.
I have been at UVa for six months. I started my medical career at The Ohio State University College of Medicine for medical school in Columbus, Ohio. I completed my internal medicine residency at Mayo Clinic in Rochester, Minnesota, and fellowship in Hematology and Medical Oncology at Georgetown University in Washington, DC.

Why Healthcare?
I was drawn to a career in healthcare due to a lifelong love of science and a desire to work closely with patients to provide high-quality care and help patients through trying times. My research interest is driven by my desire to see better patient outcomes. I am interested in cancer therapeutics focusing on drug development and early phase clinical trials, bringing new technologies to improve healthcare systems and healthcare delivery, and improving healthcare access in research-poor settings. I also enjoy working with students and trainees and love the enthusiasm and curiosity they bring to healthcare teams.

What brought you to Charlottesville?
My wife and I sought UVa for the opportunity to provide cutting-edge care, work and learn from excellent peers and mentors, and be part of a warm, collegial, and collaborative working environment. We love hiking, being outdoors, and great food, which made us always intrigued by Charlottesville and has made us love living here.

What excites you about your work?
My excitement about my work comes from the opportunity to work with patients and help them through trying times I feel honored by the trust given to me to help guide patients through their Oncologic care. I am also excited by research opportunities to bring novel therapies to my patients and work on improving outcomes.

What do you enjoy doing on the weekend?
My wife and I love hiking and trying different foods – cooking together and eating out at various restaurants. We also love traveling – we often take weekend trips to DC, Richmond, and other parts of Virginia. We also love watching movies and TV shows.

What is your favorite vacation/activity spot?
We love cultural trips where we can experience different cultures and food. We went to Japan last June and loved it. I would love to go there again.

Who is the person you admire most, and why?
The person I admire most is my wife because she can balance multiple facets of her life and devote herself fully to each one. She is an ophthalmology resident at UVa, but also is incredibly present, loving, and generous as a wife, daughter, sister, and friend. She is also my go-to person for advice, as she always has the wisdom to provide the correct answer or guidance in any situation.

What is a talent or skill you don’t have that you wish you did?
I wish I had a musical or artistic talent. I would love to be able to play an instrument. I played saxophone in middle school but did not keep up with it.

Favorite fictional characters?
I am a big Harry Potter fan and love those three main characters – Harry Potter, Hermoine Granger, and Ron Weasley.

Would you rather do one thing extraordinarily well or ten things admirably well?
I would rather do ten things admirably well. I like the idea of being well-balanced with multiple talents/interests.

What is the last book you read for pleasure?
The last book I read for pleasure is Pachinko, a multi-generational story about a Korean family and their journey before, during, and after World War II.

What’s the most unusual thing you have ever eaten?
I once ate a fried cricket.
APP PROFILE - Amelia Hodson

Tell us a little bit about yourself.
I’ve been at UVA for 17 years. I started as an associate’s degree RN in the NICU and earned my BSN in 2005. Around that time, I found my true calling in Oncology, earned my MSN, and have been part of UVA’s Cancer Center ever since!

Why healthcare?
In high school, I knew I enjoyed science and was interested in medicine, so I stumbled into nursing. It took me about eight years into my nursing career to discover my love for Oncology (but that’s the great thing about nursing: you can evolve and change your focus and practice easily). In oncology nursing, I’ve had several roles: an infusion nurse, RN Research Coordinator, inpatient oncology and SCT nurse, and a Hematology/Oncology APP. I’ve stayed in healthcare these last 18 years because of the patients. Illness is an inescapable part of life, and cancer is truly scary, but it is gratifying to be able to provide help and support to people through the most challenging times of their lives.

What brought you to Charlottesville?
UVA and my husband! It’s a cute story. After earning my ADN, I moved to Boston, but my boyfriend didn’t follow me. Instead, he transferred his job to Charlottesville because he said he knew I would end up at UVA eventually. As it turned out, he was right! After one year in Boston, I applied for and accepted a nursing job at UVA, and that boyfriend quickly became my husband! Seventeen years later, we love calling Charlottesville home – though we bought land and built our house about 30 minutes outside of Charlottesville after the first few years of living in town!

What excites you about your work?
I love my job! It is the exact role I dreamed of when I decided to return to school to become a Nurse Practitioner. Before starting my MSN program, I worked with Dr. Keng as a clinical research nurse coordinator in the leukemia clinic for several years. He mentored me and encouraged me to continue my education to become an APP, and I’m forever grateful to him. I work closely with Dr. El Chaer, our Nurse Coordinator Sam, and pharmacist Dr Jones in our Myeloid Malignancy Clinic. Myeloid malignancies are fascinating, and our patients challenge and humble me daily. The most exciting thing is that I’ve only worked with this disease population in various roles for less than a decade. Still, I’m seeing drastic improvements in available therapies, treatment tolerability, and survival outcomes. In our clinic, we often joke that Dr. El Chaer knows about the most recent practice-changing article less than five minutes after its publication or even pending its publication. He immediately shares that information with the team, but honestly, this is the most exciting part of my work and the team dynamic I’m so lucky to be a part of! Every new study and drug is a step in the right direction. It means hope for the future of patients with a severe diagnosis!

What do you enjoy doing on the weekend?
The weekends just are not long enough! I love many hobbies, but I do not have enough time to do everything I want! One of my biggest hobbies currently is horseback riding. I have always wanted to ride but never did until two years ago when I decided to join my daughter in lessons at a local barn. After a few months of lessons, I was given the opportunity to buy a horse of my own, and it has been quite the experience! Riding and maintaining our little “farm” takes up much of the weekend. I also love family time, gardening, cooking, reading, being outside, long-distance running, and going to our favorite local vineyard (Keswick)!

Do you have any pets?
In addition to my horse, Locksley, I have a German Shepherd named Delta and a miniature donkey named Biscuit. Biscuit is the crowd favorite and the cutest and sweetest creature on earth.

Who is the person you admire most, and why?
At the risk of sounding corny or cliché, I will say the person I admire the most is my husband, Wilby. In 2019, he was diagnosed with stage IVA non-small cell lung cancer. As a young, healthy, non-smoker, this diagnosis was beyond heartbreaking and changed our lives. He has had a very complex course with over two years of nearly continuous chemotherapy, three thoracotomies with a complete lobectomy and several segmentectomies, and four rounds of radiation to date. He never missed coaching our son’s football games and refused to sit back and take it easy at our daughter’s horse shows despite recovering from hard chemo and intense surgeries. He has never allowed cancer to come between him and being the best father and husband. When I decided to bring my horse home, he made my dream his passion. I drew a picture of my ideal barn, and he built it for me. He never hesitated to help me with all the other projects needed to make our home a “little farm.” All this is done while missing substantial lung tissue and always looming uncertainty about the future. He rarely missed work throughout all his treatments and is truly loved by his peers and employees. We still live our lives three months at a time, from scan to scan, but Wilby has handled every step of this process with astounding resilience and grace. We have so much love and gratitude for Dr. Hall, Dr. Martin, Dr. Larner, and Wilby’s healthcare team members for getting us to this point. We know our future is in the most capable hands with them.

What is the best advice anyone ever gave you?
“Eyes up, leg on.” This is a saying that my riding instructor yells at me often, and although it applies to jumping over fences, I think it translates pretty well to life. Whatever obstacles may come are best handled by looking ahead instead of down and pushing forward instead of shying away.
The fourth annual Michael J. Weber Symposium will take place on Friday, October 11, 2024, at the UVA Health System (venue to be determined). It will be organized by the University of Virginia Comprehensive Cancer Center (UVACCC) and co-sponsored by the Center for RNA Science and Medicine.

The theme of the symposium is RNA and Cancer.

The symposium will feature five world renowned speakers including a Nobel laureate.

The Michael J. Weber Symposium was established to honor the life and achievements of Michael Weber, a renowned scientist, professor and former UVACCC Director. The symposium aims to bring together cancer researchers and clinicians to present their findings on cancer research, with a focus on integrating basic, translational, and population science research with clinical trials and compassionate patient care.

Questions? Email Erin Erickson at ejh8k@uvahealth.org

Tell us a little bit about yourself.
I have been at UVA for a long time. I started as a health unit coordinator in an inpatient unit. After some time, I moved over to Heme Onc. Being at UVA for years in an administrative support role led me to my current position. It also led to me getting my Master’s Degree in Health Sciences Administration.

What brought you to Charlottesville?
I was born and raised here in Charlottesville.

What excites you about your work?
Working with my co-workers excites me about my work.

What do you enjoy doing on the weekend?
On the weekends, I enjoy watching sports and hanging out with friends.

What is a talent or skill you don’t have that you wish you did?
I wish I could crochet.

Would you rather do one thing extraordinarily well or ten things admirably well?
I would rather do ten things admirably well.

Staff Profile - Janet Tillage

Tell us a little bit about yourself.
I have been at UVA for a long time. I started as a health unit coordinator in an inpatient unit. After some time, I moved over to Heme Onc. Being at UVA for years in an administrative support role led me to my current position. It also led to me getting my Master’s Degree in Health Sciences Administration.

What brought you to Charlottesville?
I was born and raised here in Charlottesville.

What excites you about your work?
Working with my co-workers excites me about my work.

What do you enjoy doing on the weekend?
On the weekends, I enjoy watching sports and hanging out with friends.

What is a talent or skill you don’t have that you wish you did?
I wish I could crochet.

Would you rather do one thing extraordinarily well or ten things admirably well?
I would rather do ten things admirably well.